Back to top
more

Neogen (NEOG)

(Delayed Data from NSDQ)

$4.68 USD

4.68
4,712,984

+0.02 (0.43%)

Updated Aug 4, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Neogen (NEOG) to Report Q2 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

EYE or NEOG: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EYE vs. NEOG: Which Stock Is the Better Value Option?

Zacks Equity Research

Neogen's (NEOG) Food Safety Test Receives AOAC Clearance

by Zacks Equity Research

Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.

Zacks Equity Research

Why Is Neogen (NEOG) Down 2% Since Last Earnings Report?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Zacks Equity Research

Neogen (NEOG) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -3.45% and -3.47%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Neogen Forms Partnership With IGS to Enhance Beef Profile

by Zacks Equity Research

Neogen (NEOG), through the IGS partnership, aims to help cattle producers choose better cattle and enhance their productivity.

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety

by Zacks Equity Research

Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.

Zacks Equity Research

Why Is Neogen (NEOG) Up 4.4% Since Last Earnings Report?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Zacks Equity Research

Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.

Zacks Equity Research

Neogen (NEOG) Tops Q4 Earnings Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of 7.14% and -1.09%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline

by Zacks Equity Research

Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Hold Onto Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors' trust continues to be high in Neogen (NEO), thanks to strength in its Food Safety and Genomic businesses.

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Zacks Equity Research

Why Is Neogen (NEOG) Up 4.2% Since Last Earnings Report?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Neogen Hurt by Weakness in Animal Safety, Currency Woes

by Zacks Equity Research

Neogen (NEOG) exits fiscal third quarter on a disappointing note due to poor performance of Animal Safety segment.

Zacks Equity Research

Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3

by Zacks Equity Research

Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.

Zacks Equity Research

Earnings Preview: Neogen (NEOG) Q3 Earnings Expected to Decline

by Zacks Equity Research

Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Neogen Gains on Strong Genomic Arm Amid Stiff Competition

by Zacks Equity Research

Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.

Zacks Equity Research

Why Is Neogen (NEOG) Up 9.4% Since Last Earnings Report?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.